Sugi Predict

Sugi Predict / Compounds / SCHEMBL1817841

SCHEMBL1817841

SCHEMBL1817841

COCCc1ccc(Br)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GBA1 P04062 1/20 0.43
▸ ATM Q13315 1/20 0.36
▸ GRM2 Q14416 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ PDE2A O00408 1/20 0.34
▸ PDE8A O60658 1/20 0.34
▸ PDE5A O76074 1/20 0.34
▸ PDE9A O76083 1/20 0.34
▸ PDE6A P16499 1/20 0.34
▸ HTR2C P28335 1/20 0.34
▸ HTR7 P34969 1/20 0.34
▸ HTR2B P41595 1/20 0.34
▸ PDE1B Q01064 1/20 0.34
▸ PDE4D Q08499 1/20 0.34
▸ PDE7A Q13946 1/20 0.34
▸ PDE3A Q14432 1/20 0.34
▸ PDE11A Q9HCR9 1/20 0.34
▸ PDE10A Q9Y233 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1820441 0.89 GBA1 (0.41) GBA1ATMGRM2TSHRALDH1A1
SCHEMBL12837851 0.85 GBA1 (0.41) GBA1ATMGRM2TSHRALDH1A1
SCHEMBL2147686 0.80 GBA1 (0.40) GBA1ATMGRM2ALDH1A1MAPT
SCHEMBL1855342 0.80 GBA1 (0.46) GBA1ATMGRM2TSHRALDH1A1
SCHEMBL6935097 0.78 CCR1 (0.41) PDE2APDE8APDE5APDE9APDE6A
SCHEMBL31729646 0.78 GBA1 (0.52) GBA1ATMGRM2TSHRALDH1A1
SCHEMBL3231706 0.78 GBA1 (0.52) GBA1ATMGRM2TSHRALDH1A1
SCHEMBL23515097 0.78 ALDH1A1 (0.40) GBA1TSHRALDH1A1MAPTKDM4E
SCHEMBL4056065 0.78 GBA1 (0.38) GBA1GRM2TSHRHTR2CALDH1A1
SCHEMBL19313495 0.77 PDE2A (0.34) PDE2APDE8APDE5APDE9APDE6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12227507-B2 Pharmaceutical compounds PFIZER INC. (US) 2025-02-18 — — US disclosed
CN-114555604-B Pharmaceutical compounds 辉瑞公司 2024-11-15 — — CN disclosed
US-11634425-B2 Pharmaceutical compounds PFIZER INC. (US) 2023-04-25 — — US disclosed
US-11634425-B2 Pharmaceutical compounds PFIZER INC. (US) 2023-04-25 — — US disclosed
US-20220324873-A1 PHARMACEUTICAL COMPOUNDS PFIZER INC. 2022-10-13 — — US disclosed
US-20220306639-A1 PHARMACEUTICAL COMPOUNDS PFIZER INC. 2022-09-29 — — US disclosed
EP-4017856-A1 PHARMACEUTICAL COMPOUNDS Reviral Limited (GB) 2022-06-29 — — EP disclosed
CN-114555604-A Pharmaceutical compounds 瑞威有限公司 2022-05-27 — — CN disclosed
WO-2021032992-A1 PHARMACEUTICAL COMPOUNDS ReViral Limited (GB) 2021-02-25 — — WO disclosed
WO-2021032992-A1 PHARMACEUTICAL COMPOUNDS ReViral Limited (GB) 2021-02-25 — — WO disclosed
US-20120220581-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS JANSSEN-CILAG, S.A. (ES) 2012-08-30 — — US disclosed
US-20120220581-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS JANSSEN-CILAG, S.A. (ES) 2012-08-30 — — US disclosed
CN-102596961-A Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors JANSSEN PHARMACEUTICA NV 2012-07-18 — — CN disclosed
US-20110269752-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS PASTOR-FERNANDEZ JOAQUIN 2011-11-03 — — US disclosed
US-20110269752-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS PASTOR-FERNANDEZ JOAQUIN 2011-11-03 — — US disclosed
US-20110269752-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS PASTOR-FERNANDEZ JOAQUIN 2011-11-03 — — US disclosed
WO-2011110545-A1 IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES JANSSEN PHARMACEUTICA NV (BE) 2011-09-15 — — WO disclosed
WO-2011110545-A1 IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES JANSSEN PHARMACEUTICA NV (BE) 2011-09-15 — — WO disclosed
WO-2011051342-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-05-05 — — WO disclosed
WO-2011051342-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-05-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12227507-B2 Pharmaceutical compounds CHRNA6, GABRA6, CHRNA7 GBA1 3034/4885ATM 4753/4885GRM2 435/4885
US-20120220581-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS PDE12, PDE10A, PDE5A GBA1 409/4885ATM 3057/4885GRM2 1261/4885
US-11634425-B2 Pharmaceutical compounds GABRA6, CHRNA6, CNR1 GBA1 2810/4885ATM 4735/4885GRM2 628/4885
US-20220306639-A1 PHARMACEUTICAL COMPOUNDS CHRNA6, GABRA6, CHRNA7 GBA1 3034/4885ATM 4753/4885GRM2 435/4885
US-20220324873-A1 PHARMACEUTICAL COMPOUNDS GABRA6, CNR1, CHRNA6 GBA1 3095/4885ATM 4718/4885GRM2 482/4885
US-20110269752-A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS PDE12, PDE10A, PDE5A GBA1 409/4885ATM 3057/4885GRM2 1261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.